Finally, optimal HF guideline directed medical therapy did not include sodium-glucose cotransporter-2 (SGLT-2) inhibitors, which lacked evidence for the management of HFpEF at the time the study was performed. This evidence concerns the gene SLC5A2 and hydrops fetalis.